The league table of top-selling drugs by global revenues saw a considerable shake-up in 2023, as COVID-19 vaccine and therapeutic sales plummeted, GLP-1 inhibitors took the market by storm, and one-time best-seller Humira lost US patent protection.
One of the most notable features of the top 20 list in 2023 was the huge fall in aggregate revenues....